37799-77-2

Usage

InChI:InChI=1/C12H17N3O4/c1-4-18-11(16)9(12(17)19-5-2)8-13-10-6-7-14-15(10)3/h6-8,13H,4-5H2,1-3H3

Upstream product

• 1192-21-8 5-Amino-1-methylpyrazole 
• 87-13-8 diethyl 2-ethoxymethylenemalonate 

Downstream Products

• 1421702-80-8 N-cyclohexyl-4,7-dihydro-1-methyl-4-oxo-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 
• 1421702-33-1 C₁₉H₂₈N₄O₂ 
• 675111-88-3 4-chloro-1-methyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid 
• 37801-57-3 4-chloro-1-methyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid ethyl ester 

Relevant academic research and scientific papers

Design, synthesis, and pharmacological properties of new heteroarylpyridine/heteroarylpyrimidine derivatives as CB2 cannabinoid receptor partial agonists

Recent developments indicate that CB2 receptor ligands have the potential to become therapeutically important. To explore this potential, it is necessary to develop compounds with high affinity for the CB2 receptor. Very recently, we

Discovery of new orally active phosphodiesterase (PDE4) inhibitors

A series of 4-anilinopyrazolopyridine derivatives were synthesized and biologically evaluated as inhibitors of phosphodiesterase (PDE4). Chemical modification of 3, a structurally new chemical lead that was found in our in-house library, was focused on 1- and 3-substituents. Full details of the discovery of a new orally active chemical lead 5 are presented. Structure-activity relationship data, pharmacological evaluation, and the subtype selectivity study are also presented.